Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
8.94
-0.18 (-1.97%)
At close: Jun 27, 2025, 4:00 PM
8.94
0.00 (0.00%)
After-hours: Jun 27, 2025, 4:34 PM EDT
Lyell Immunopharma Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Lyell Immunopharma stock ranges from a low of $10 to a high of $20. The average analyst price target of $15 forecasts a 67.79% increase in the stock price over the next year.
Price Target: $15.00 (+67.79%)
Analyst Consensus: Sell
Analyst Ratings
The average analyst rating for Lyell Immunopharma stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $10 | Hold | Maintains | $1 → $10 | +11.86% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | +123.71% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | +123.71% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | +123.71% | Nov 12, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $120 → $20 | Strong Buy → Sell | Downgrades | $120 → $20 | +123.71% | Oct 30, 2024 |
Financial Forecast
Revenue This Year
24.14K
from 61.00K
Decreased by -60.42%
Revenue Next Year
20.74K
from 24.14K
Decreased by -14.11%
EPS This Year
-14.33
from -26.23
EPS Next Year
-12.99
from -14.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 64,050 | 64,050 | 64,050 |
| Avg | 24,143 | 20,737 | 31,110 |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 5.0% | 165.3% | 208.9% |
| Avg | -60.4% | -14.1% | 50.0% |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -10.50 | -6.30 | -3.52 |
| Avg | -14.33 | -12.99 | -8.64 |
| Low | -16.27 | -16.86 | -13.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.